Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
TARRYTOWN, N.Y., Aug. 6, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial and operating results for the second quarter of 2013 and provided an update on development programs.
The Company reported total revenues of $458 million in the second quarter and $897 million in the first half of 2013, compared to $304 million in the second quarter and $536 million in the first half of 2012. EYLEA U.S. net product sales grew 70% to $330 million in the second quarter of 2013 from $194 million in the second quarter of 2012.
Hey, check out all the research scientist jobs. Post your resume today!
TARRYTOWN, N.Y., Aug. 6, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial and operating results for the second quarter of 2013 and provided an update on development programs.
The Company reported total revenues of $458 million in the second quarter and $897 million in the first half of 2013, compared to $304 million in the second quarter and $536 million in the first half of 2012. EYLEA U.S. net product sales grew 70% to $330 million in the second quarter of 2013 from $194 million in the second quarter of 2012.
Hey, check out all the research scientist jobs. Post your resume today!
